Key Points
-
Prevalent ERG oncogene activation (predominantly owing to TMPRSS2–ERG fusion) is one of the most widely studied and validated alterations in a prostate cancer driver gene
-
The majority of studies establishing ERG prevalence in prostate cancer have focused on patients of European ancestry
-
The frequency of ERG-oncoprotein-positive prostate cancers is substantially lower among African American men (20–30%) than among white Americans (50–60%)
-
Frequencies of ERG are lowest (10–20%) in Asian populations, but data are variable across studies and methodologies
-
ERG positive prostate tumour foci are relatively homogenous for immunostaining, but inconsistencies in frequency variations can still result from sampling bias owing to interfocal heterogeneity of ERG in the multifocal context of prostate cancer
-
Detection of TMPRSS2–ERG fusions using fluorescence in situ hybridization, or of ERG oncoprotein using immunohistochemistry, are highly concordant, but immunohistochemistry demonstrates less variability and might be more applicable for clinical use
Abstract
Emerging observations emphasize a distinct biology of prostate cancer among men of different ethnicities and races, as demonstrated by remarkable differences in the frequency of ERG oncogenic activation, one of the most common and widely studied prostate cancer driver genes. Worldwide assessment of ERG alterations frequencies show consistent trends, with men of European ancestry having the highest rates of alteration and men of African or Asian ancestries having considerably lower alteration rates. However, data must be interpreted cautiously, owing to variations in assay platforms and specimen types, as well as ethnic and geographical classifications. Many opportunities and challenges remain in assessing cancer-associated molecular alterations at a global level, and these need to be addressed in order to realize the true potential of precision medicine for all cancer patients.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2017. CA Cancer J. Clin. 67, 7–30 (2017).
Kumar-Sinha, C., Tomlins, S. A. & Chinnaiyan, A. M. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer 8, 497–511 (2008).
Rosen, P. et al. Clinical potential of the ERG oncoprotein in prostate cancer. Nat. Rev. Urol. 9, 131–137 (2012).
Rubin, M. A., Maher, C. A. & Chinnaiyan, A. M. Common gene rearrangements in prostate cancer. J. Clin. Oncol. 29, 3659–3668 (2011).
An, J. et al. Truncated ERG Oncoproteins from TMPRSS2-ERG fusions are resistant to SPOP-mediated proteasome degradation. Mol. Cell 59, 904–916 (2015).
Gan, W. et al. SPOP promotes ubiquitination and degradation of the ERG oncoprotein to suppress prostate cancer progression. Mol. Cell 59, 917–930 (2015).
Mani, R. S. et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 326, 1230 (2009).
Haffner, M. C. et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat. Genet. 42, 668–675 (2010).
Lin, C. et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 139, 1069–1083 (2009).
Beltran, H. et al. Aggressive variants of castration-resistant prostate cancer. Clin. Cancer Res. 20, 2846–2850 (2014).
Petrovics, G. et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24, 3847–3852 (2005).
Hu, Y. et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin. Cancer Res. 14, 4719–4725 (2008).
Magi-Galluzzi, C. et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 71, 489–497 (2011).
Rosen, P. et al. Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology 80, 749–753 (2012).
Powell, I. J. & Bollig-Fischer, A. Minireview: the molecular and genomic basis for prostate cancer health disparities. Mol. Endocrinol. 27, 879–891 (2013).
Farrell, J., Petrovics, G., McLeod, D. G. & Srivastava, S. Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. Int. J. Mol. Sci. 14, 15510–15531 (2013).
McGinley, K. F., Tay, K. J. & Moul, J. W. Prostate cancer in men of African origin. Nat. Rev. Urol. 13, 99–107 (2016).
Rebbeck, T. R. & Haas, G. P. Temporal trends and racial disparities in global prostate cancer prevalence. Can. J. Urol. 21, 7496–7506 (2014).
DeSantis, C. E. et al. Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J. Clin. 66, 290–308 (2016).
Chornokur, G., Dalton, K., Borysova, M. E. & Kumar, N. B. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate 71, 985–997 (2011).
Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005).
Furusato, B. et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 13, 228–237 (2010).
Park, K. et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12, 590–598 (2010).
Miettinen, M. et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am. J. Surg. Pathol. 35, 432–441 (2011).
Baltzinger, M., Mager-Heckel, A. M. & Remy, P. Xl erg: expression pattern and overexpression during development plead for a role in endothelial cell differentiation. Dev. Dyn. 216, 420–433 (1999).
Iwamoto, M. et al. Transcription factor ERG and joint and articular cartilage formation during mouse limb and spine skeletogenesis. Dev. Biol. 305, 40–51 (2007).
Mohamed, A. A. et al. Ets family protein, erg expression in developing and adult mouse tissues by a highly specific monoclonal antibody. J. Cancer 1, 197–208 (2010).
Nelson, P. S. et al. Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc. Natl Acad. Sci. USA 96, 3114–3119 (1999).
Perner, S. et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am. J. Surg. Pathol. 31, 882–888 (2007).
Braun, M. et al. ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer—a comparative study of two monoclonal antibodies. Prostate Cancer Prostatic Dis. 15, 165–169 (2012).
Sun, C. et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27, 5348–5353 (2008).
King, J. C. et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat. Genet. 41, 524–526 (2009).
Carver, B. S. et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 41, 619–624 (2009).
Zong, Y. et al. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc. Natl Acad. Sci. USA 106, 12465–12470 (2009).
Chen, Y. et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat. Med. 19, 1023–1029 (2013).
Tomlins, S. A. et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10, 177–188 (2008).
Klezovitch, O. et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc. Natl Acad. Sci. USA 105, 2105–2110 (2008).
Sreenath, T. L. et al. ETS related gene mediated androgen receptor aggregation and endoplasmic reticulum stress in prostate cancer development. Sci. Rep. 7, 1109 (2017).
Khemlina, G., Ikeda, S. & Kurzrock, R. Molecular landscape of prostate cancer: implications for current clinical trials. Cancer Treat. Rev. 41, 761–766 (2015).
Brenner, J. C. et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19, 664–678 (2011).
Asangani, I. A. et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510, 278–282 (2014).
Blee, A. M., Liu, S., Wang, L. & Huang, H. BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion. Oncotarget 7, 38319–38332 (2016).
Fortson, W. S. et al. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. Int. J. Oncol. 39, 111–119 (2011).
Kim, T. D., Shin, S. & Janknecht, R. ETS transcription factor ERG cooperates with histone demethylase KDM4A. Oncol. Rep. 35, 3679–3688 (2016).
Kao, C. J. et al. miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene 33, 2495–2503 (2014).
Mohamed, A. A. et al. Structure-activity studies and biological evaluations of ERGi-USU, a highly selective inhibitor for ERG-positive prostate cancer cells [abstract]. Cancer Res. 77 (Suppl. 13), 1183 (2017).
Wang, S. et al. Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. Proc. Natl Acad. Sci. USA 111, 4251–4256 (2014).
Nhili, R. et al. Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines. Nucleic Acids Res. 41, 125–138 (2013).
Hargrove, A. E. et al. Tumor repression of VCaP xenografts by a pyrrole-imidazole polyamide. PLoS ONE 10, e0143161 (2015).
Mancarella, C. et al. ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents. Oncotarget 6, 16611–16622 (2015).
Wang, X. et al. Development of peptidomimetic inhibitors of the ERG gene fusion product in prostate cancer. Cancer Cell 31, 844–847 (2017).
Butler, M. S. et al. Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer. Oncotarget 8, 42438–42454 (2017).
Rahim, S. et al. YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. PLoS ONE 6, e19343 (2011).
Shao, L. et al. Celastrol suppresses tumor cell growth through targeting an AR-ERG-NF-kappaB pathway in TMPRSS2/ERG fusion gene expressing prostate cancer. PLoS ONE 8, e58391 (2013).
Mohamed, A. A. et al. Synergistic activity with NOTCH inhibition and androgen ablation in ERG-positive prostate cancer cells. Mol. Cancer Res. http://dx.doi.org/10.1158/1541-7786.MCR-17-0058 (2017).
Urbinati, G. et al. Antineoplastic effects of siRNA against TMPRSS2-ERG junction oncogene in prostate cancer. PLoS ONE 10, e0125277 (2015).
Graff, R. E. et al. The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer. Prostate 75, 897–906 (2015).
Gsponer, J. R. et al. ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 17, 126–131 (2014).
Galletti, G. et al. ERG induces taxane resistance in castration-resistant prostate cancer. Nat. Commun. 5, 5548 (2014).
Huang, K. C. et al. The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy. Cancer Biol. Ther. 15, 1120–1128 (2014).
Lotan, T. L. et al. PTEN loss as determined by clinical-grade immunohistochemistry assay is associated with worse recurrence-free survival in prostate cancer. Eur. Urol. Focus 2, 180–188 (2016).
Vanaja, D. K., Cheville, J. C., Iturria, S. J. & Young, C. Y. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 63, 3877–3882 (2003).
Farrell, J. et al. Predominance of ERG-negative high-grade prostate cancers in African American men. Mol. Clin. Oncol. 2, 982–986 (2014).
Rice, K. R. et al. Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer. Clin. Cancer Res. 16, 1572–1576 (2010).
Mosquera, J. M. et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin. Cancer Res. 15, 4706–4711 (2009).
Mao, X. et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res. 70, 5207–5212 (2010).
Powell, I. J., Dyson, G., Chinni, S. R. & Bollig-Fischer, A. Considering race and the potential for ERG expression as a biomarker for prostate cancer. Per. Med. 11, 409–412 (2014).
Blattner, M. et al. SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia 16, 14–20 (2014).
Khani, F. et al. Evidence for molecular differences in prostate cancer between African American and Caucasian men. Clin. Cancer Res. 20, 4925–4934 (2014).
Nishijima, J. et al. Clinical significance of ERG rearrangement subtype and its association with increased p53 expression in Japanese and German prostate cancer. Neoplasma 62, 278–287 (2015).
Tomlins, S. A. et al. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. Eur. Urol. 68, 555–567 (2015).
Pettersson, A. et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 21, 1497–1509 (2012).
Center, M. M. et al. International variation in prostate cancer incidence and mortality rates. Eur. Urol. 61, 1079–1092 (2012).
Adeloye, D. et al. An estimate of the incidence of prostate cancer in Africa: a systematic review and meta-analysis. PLoS ONE 11, e0153496 (2016).
Kelly, G. M. et al. ERG oncoprotein expression in prostate carcinoma patients of different ethnicities. Mol. Clin. Oncol. 3, 23–30 (2015).
Wallace, T. A. et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 68, 927–936 (2008).
Yamoah, K. et al. Novel biomarker signature that may predict aggressive disease in African American men with prostate cancer. J. Clin. Oncol. 33, 2789–2796 (2015).
Petrovics, G. et al. A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men. EBioMedicine 2, 1957–1964 (2015).
Lindquist, K. J. et al. Mutational landscape of aggressive prostate tumors in African American men. Cancer Res. 76, 1860–1868 (2016).
Huang, F. W. et al. Exome sequencing of African-American prostate cancer reveals loss-of-function ERF mutations. Cancer Discov. http://dx.doi.org/10.1158/2159-8290.CD-16-0960 (2017).
Tosoian, J. J. et al. Prevalence and prognostic significance of PTEN loss in African-American and European-American men undergoing radical prostatectomy. Eur. Urol. 71, 697–700 (2017).
Wang, Z. Distinct genomic alterations in prostate tumors from African American men. EBioMedicine 2, 1850–1851 (2015).
Cullen, J. et al. Predicting prostate cancer progression as a function of ERG status, race and obesity in a longitudinal patient cohort. Eur. Urol. Focus http://dx.doi.org/10.1016/j.euf.2017.02.016 (2017).
Miyagi, Y. et al. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Mod. Pathol. 23, 1492–1498 (2010).
Sun, Q. P. et al. Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study. J. Mol. Diagn. 12, 718–724 (2010).
Jiang, H. et al. TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer. Tumour Biol. 37, 12397–12402 (2016).
Falzarano, S. M. et al. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch. 459, 441–447 (2011).
Minner, S. et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin. Cancer Res. 17, 5878–5888 (2011).
Ke Zhou, C. et al. TMPRSS2-ERG gene fusions in prostate cancer of West African men and a meta-analysis of racial differences. Am. J. Epidemiol. http://dx.doi.org/10.1093/aje/kwx235 (2017).
Furusato, B. et al. Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort: diagnostic use in Japanese prostate cancer patients. Pathol. Int. 61, 409–414 (2011).
Suh, J. H., Park, J. W., Lee, C. & Moon, K. C. ERG immunohistochemistry and clinicopathologic characteristics in Korean prostate adenocarcinoma patients. Korean J. Pathol. 46, 423–428 (2012).
Kimura, T. et al. Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients. Pathol. Int. 62, 742–748 (2012).
Rawal, S. et al. Low frequency of the ERG oncogene alterations in prostate cancer patients from India. J. Cancer 4, 468–472 (2013).
Zhau, H. E., Li, Q. & Chung, L. W. Interracial differences in prostate cancer progression among patients from the United States, China and Japan. Asian J. Androl. 15, 705–707 (2013).
Raymundo, E. M. et al. Increased association of the ERG oncoprotein expression in advanced stages of prostate cancer in Filipinos. Prostate 74, 1079–1085 (2014).
Ateeq, B. et al. Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India. Prostate 75, 1051–1062 (2015).
DeMarzo, A. M., Nelson, W. G., Isaacs, W. B. & Epstein, J. I. Pathological and molecular aspects of prostate cancer. Lancet 361, 955–964 (2003).
Kajdacsy-Balla, A. et al. Practical aspects of planning, building, and interpreting tissue microarrays: the Cooperative Prostate Cancer Tissue Resource experience. J. Mol. Histol 38, 113–121 (2007).
Boström, P. J. et al. Genomic predictors of outcome in prostate cancer. Eur. Urol. 68, 1033–1044 (2015).
Qi, M. et al. ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients. PLoS ONE 9, e84959 (2014).
Suryavanshi, M. et al. Weaker ERG expression in patients with ERG-positive prostate cancer is associated with advanced disease and weaker androgen receptor expression: an Indian outlook. Urol. Oncol. 33, 331.e9–331.e15 (2015).
Kim, S. H. et al. Overexpression of ERG and wild-type PTEN are associated with favorable clinical prognosis and low biochemical recurrence in prostate cancer. PLoS ONE 10, e0122498 (2015).
Dong, J., Xiao, L., Sheng, L., Xu, J. & Sun, Z. Q. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China. Asian Pac. J. Cancer Prev. 15, 3099–3103 (2014).
Mersha, T. B. & Abebe, T. Self-reported race/ethnicity in the age of genomic research: its potential impact on understanding health disparities. Hum. Genomics 9, 1 (2015).
Baye, T. M. & Wilke, R. A. Mapping genes that predict treatment outcome in admixed populations. Pharmacogenomics J. 10, 465–477 (2010).
Price, A. L. et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 38, 904–909 (2006).
Yaeger, R. et al. Comparing genetic ancestry and self-described race in African Americans born in the United States and in Africa. Cancer Epidemiol. Biomarkers Prev. 17, 1329–1338 (2008).
Keen-Kim, D. et al. Overrepresentation of rare variants in a specific ethnic group may confuse interpretation of association analyses. Hum. Mol. Genet. 15, 3324–3328 (2006).
Noh, B. J., Sung, J. Y., Kim, Y. W., Chang, S. G. & Park, Y. K. Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer. Oncol. Lett. 11, 3621–3630 (2016).
Sung, J. Y. et al. Correlation of ERG immunohistochemistry with molecular detection of TMPRSS2-ERG gene fusion. J. Clin. Pathol. 69, 586–592 (2016).
Jung, W. Y. et al. AZGP-1 immunohistochemical marker in prostate cancer: potential predictive marker of biochemical recurrence in post radical prostatectomy specimens. Appl. Immunohistochem. Mol. Morphol. 22, 652–657 (2014).
Xue, L. et al. Chinese and Western prostate cancers show alternate pathogenetic pathways in association with ERG status. Am. J. Cancer Res. 2, 736–744 (2012).
Pan, X. et al. The expression profile and prognostic value of SPINK1 in initially diagnosed bone metastatic prostate cancer. Prostate 76, 823–833 (2016).
Kaczmarczyk, K. et al. Frequency of ERG-positive prostate carcinoma in Polands. Pol. J. Pathol. 64, 175–179 (2013).
Strand, S. H. et al. High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer. Clin. Epigenetics 7, 111 (2015).
Hoogland, A. M. et al. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod. Pathol. 25, 471–479 (2012).
Schaefer, G. et al. Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer. Prostate Cancer Prostatic Dis. 16, 132–138 (2013).
Hagen, R. M. et al. Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence. Am. J. Clin. Pathol. 142, 533–540 (2014).
Pal, R. P. et al. Immunocytochemical detection of ERG expression in exfoliated urinary cells identifies with high specificity patients with prostate cancer. BJU Int. 117, 686–696 (2016).
Brooks, J. D. et al. Evaluation of ERG and SPINK1 by immunohistochemical staining and clinicopathological outcomes in a multi-institutional radical prostatectomy cohort of 1067 patients. PLoS ONE 10, e0132343 (2015).
Acknowledgements
Authors express sincere thanks to Mr. Stephen Doyle for the art work. The opinions or assertions contained herein are the private ones of the authors and are not to be construed as official or reflecting the views of the Department of Defense, the Uniformed Services University of the Health Sciences or any other agency of the U.S. Government.
Author information
Authors and Affiliations
Contributions
All authors researched data for article; A. D., J. S. and S. S. made substantial contributions to discussion of content; A. D., J. S., M. D. and S.S. wrote the manuscript, and A. D. and S. S. reviewed and edited the manuscript before submission.
Corresponding authors
Ethics declarations
Competing interests
S. S. and A. D. are inventors of the ERG monoclonal antibody (9FY) that is licensed to Biocare Medical by The Henry M. Jackson Foundation for the Advancement of Military Medicine. The other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Sedarsky, J., Degon, M., Srivastava, S. et al. Ethnicity and ERG frequency in prostate cancer. Nat Rev Urol 15, 125–131 (2018). https://doi.org/10.1038/nrurol.2017.140
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2017.140
This article is cited by
-
Extensive germline-somatic interplay contributes to prostate cancer progression through HNF1B co-option of TMPRSS2-ERG
Nature Communications (2022)
-
Race and prostate cancer: genomic landscape
Nature Reviews Urology (2022)
-
Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes
Nature Communications (2022)
-
Epidemiology and genomics of prostate cancer in Asian men
Nature Reviews Urology (2021)
-
Prostate cancer patients’ self-reported participation in research: an examination of racial/ethnic disparities
Cancer Causes & Control (2021)